NCI
Biden Cancer Moonshot Announces New Initiatives to Improve Diagnosis, Precision Treatments
The program announced a series of new public and private initiatives and projects designed to support its stated goal of halving the cancer death rate over the next 25 years.
The NCI-led Vanguard study has selected tests from Guardant Health and ClearNote Health to move forward after a vigorous technology assessment.
BRCA2 Variants Classified in Saturation Genome Editing Studies
Research teams relied on CRISPR-Cas9-based editing and sequencing to perform high-throughput function evaluations of loss-of-function variants in exons 15 to 26 of BRCA2.
Caris Life Sciences, ECOG-ACRIN to Analyze Breast Tumor Samples From Landmark TAILORx Study
Through a new partnership, Caris will use its comprehensive genomic profiling tests to sequence more than 10,000 early-stage breast tumors collected in TAILORx.
National Cancer Institute Launches MyeloMATCH Myeloid Cancer Treatment Clinical Trial
The trial aims to enroll several thousand patients to test precision medicine treatments for bone marrow and blood cancers.